Investigational Drug Information for Vadadustat
✉ Email this page to a colleague
What is the development status for investigational drug Vadadustat?
Vadadustat is an investigational drug.
There have been 29 clinical trials for Vadadustat.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 30th 2017.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Mitsubishi Tanabe Pharma Corporation, and The University of Texas Health Science Center, Houston.
There are twenty US patents protecting this investigational drug and two hundred and sixty international patents.
Summary for Vadadustat
| US Patents | 20 |
| International Patents | 260 |
| US Patent Applications | 65 |
| WIPO Patent Applications | 41 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 3 (2017-10-30) |
| Vendors | 50 |
Recent Clinical Trials for Vadadustat
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Akebia Therapeutics | Phase 3 |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents | Akebia Therapeutics | Phase 3 |
| Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | Akebia Therapeutics | Phase 3 |
Clinical Trial Summary for Vadadustat
Top disease conditions for Vadadustat
Top clinical trial sponsors for Vadadustat
US Patents for Vadadustat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vadadustat | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Vadadustat | ⤷ Try a Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Vadadustat | ⤷ Try a Trial | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Vadadustat | ⤷ Try a Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Vadadustat | ⤷ Try a Trial | Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof | Crystal Pharmaceutical (Suzhou) Co., Ltd. (Suzhou, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vadadustat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vadadustat | Australia | AU2017261372 | 2036-05-05 | ⤷ Try a Trial |
| Vadadustat | Canada | CA3023278 | 2036-05-05 | ⤷ Try a Trial |
| Vadadustat | China | CN107847398 | 2036-05-05 | ⤷ Try a Trial |
| Vadadustat | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Try a Trial |
| Vadadustat | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
